Moderna shares fell over 10% on Friday. The latest backdrop points to a cooling of the recent cancer-vaccine-driven rally.
Recent coverage said Moderna, Inc. had surged more than 650% this year after positive phase III results for its mRNA cancer vaccine with Keytruda reshaped the company’s oncology narrative, but also noted that heavy losses and a high price-to-sales multiple have increased valuation pressure as the market awaits fuller data at the upcoming ESMO meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.